CTOs on the Move

Palisades Medical Center

www.palisadesmedical.org

 
Palisades Medical Center is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Palisades Medical Center is based in North Bergen, NJ. You can find more information on Palisades Medical Center at www.palisadesmedical.org
  • Number of Employees: 1K-5K
  • Annual Revenue: $50-100 Million

Executives

Name Title Contact Details

Similar Companies

Greensprings Assisted Living

Greensprings Assisted Living is a Prattville, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Solvay Pharmaceuticals Inc

Solvay Pharmaceuticals Inc is a Marietta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cricket Health

Cricket Health is a specialty kidney care provider of integrated nephrology and dialysis care for people with Chronic Kidney Disease (CKD) and End Stage Renal Disease (ESRD). Cricket Health delivers world-class, technology-enabled multidisciplinary care both in-person and virtually to achieve the best outcomes possible for patients and the best value for partners, keeping patients healthy and out of the hospital, accelerating access to transplant, and increasing home dialysis adoption. We are committed to aligning the success of our company with those of our partners and the patients whom we serve.

Diversified Portfolio Biotechnology

Diversified Portfolio Biotechnology is a Menlo Park, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Alnylam

Alnylam is the world`s leading RNAi therapeutics company and the first and only company to bring an RNAi medicine to market. We are developing RNAi (RNA interference) as an innovative, entirely new class of medicines to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) and ocular diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology – the discovery of RNAi, and a bold vision that this discovery could be used to silence disease-causing genes upstream of today`s medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Overall, we believe that patients shouldn`t have to wait for hope. Alnylam is turning scientific possibility into reality - in 2018, the FDA and European EMA approved of our first product, ONPATTRO (patisiran) which is also the first-ever approved RNAi therapeutic. In 2019, the FDA approved our second product, GIVLAARI (givosiran). Our robust pipeline of investigational medicines includes multiple programs in late-stage and early-stage clinical development. We are a global and diverse company of more than 1,500 people. We pride ourself on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That`s why we`ve been named a Science Magazine Top Employer for two years in a row (`19-`20), a Boston Globe Top Place to Work 5x in a row (`15-`19) and one of Fast Company`s 50 Most Innovative Companies for 2019. We are based in Cambridge, U.S., with offices throughout Europe, Asia and South America.